Cite
BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS
MLA
Pierre Fenaux, et al. “BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS.” Blood, vol. 120, Nov. 2012, p. 678. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4590649948d016e123404c3ab8b89096&authtype=sso&custid=ns315887.
APA
Pierre Fenaux, Michael Andreeff, Marina Konopleva, Beurlet Stephanie, Anne Janin, West Robert, Pierre de la Grange, Le Pogam Carole, Leboeuf Christophe, Krief Patricia, Rose Ann Padua, Petra Gorombei, Nader Omidvar, Noguera Maria-Elena, Christine Chomienne, & Pla Marika. (2012). BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS. Blood, 120, 678.
Chicago
Pierre Fenaux, Michael Andreeff, Marina Konopleva, Beurlet Stephanie, Anne Janin, West Robert, Pierre de la Grange, et al. 2012. “BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS.” Blood 120 (November): 678. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4590649948d016e123404c3ab8b89096&authtype=sso&custid=ns315887.